ArticlePloS one2025
Developing an innovation and enterprise framework for translating UK-driven global health research into commercially viable interventions: the FLIGHT study protocol.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The UK Higher Education Institution (HEI) sector faces significant challenges in translating early-stage research into commercially viable public health products, particularly in infectious diseases. This gap, often termed the "valley of death," is exacerbated by a fragmented ecosystem and unclear pathways to implementation. The FLIGHT (Framework for Leveraging Innovation in Global Health Technologies) project aims to address these challenges by enhancing the commercialisation of global health research from UK HEIs to drive economic and societal impact. Led by Liverpool School of Tropical Medicine, in partnership with London School of Hygiene and Tropical Medicine, Brighton and Sussex Medical School, and other associated partners, FLIGHT seeks to develop a best practice Innovation and Enterprise Framework (IEF) to support R&D commercialisation. This project will use a mixed-methods approach to assess existing public health R&D assets and the commercialisation knowledge and skills of HEI professionals and Early Career Researchers (ECRs) across partner institutions. Data collection will include literature reviews, surveys, qualitative interviews, and focus group discussions exploring staff and ECR's perceptions and experiences with commercialisation, to identify barriers and opportunities for improvement. Ethical considerations and participant confidentiality are central to the study design. The FLIGHT project aims to bridge critical gaps in the innovation pipeline, fostering a robust ecosystem for translating HEI research into deployable health interventions. This initiative will contribute to strengthening the UK's global health R&D commercialisation capabilities and accelerating the development and deployment of essential public health interventions. Findings will inform policy recommendations and best practice for HEI commercialisation strategies, with implications for both UK and low-and middle-income country (LMIC) contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.